| 外周血sPD-L1在小细胞肺癌患者化疗期间变化及其临床意义 |
| |
| 引用本文： | 田浩,康晓艳,杨琳,朱海波,郭伟,宋霞. 外周血sPD-L1在小细胞肺癌患者化疗期间变化及其临床意义[J]. 中国肿瘤临床, 2019, 46(9): 452-456. DOI: 10.3969/j.issn.1000-8179.2019.09.272 |
| |
| 作者姓名： | 田浩 康晓艳 杨琳 朱海波 郭伟 宋霞 |
| |
| 作者单位： | ①.山西医科大学（太原市030001） |
| |
| 基金项目： | 山西省应用基础研究面上自然基金项目201701D121093 |
| |
| 摘 要： | 目的:肿瘤微环境中,免疫相关机制使程序性死亡分子配体1(programmed death ligand 1,PD-L1)表达上调,从而异常激活PD-L1信号通路,介导肿瘤免疫逃逸。可溶性程序性死亡配体1(soluble programmed death ligand 1,sPD-L1)是PD-L1的一种存在形式。有研究证实sPD-L1在肺鳞癌及腺癌中的表达与疾病进展相关,而小细胞肺癌(small cell lung cancer,SCLC)恶性程度高侵袭性强,相关研究较少。本研究旨在观察sPD-L1在SCLC患者血浆中的表达变化及临床意义。方法:筛选2018年3月至2018年11月山西省肿瘤医院经病理学检查诊断为SCLC的初治患者94例作为试验组,选取同期健康体检者17例作为对照组,比较两组血浆sPD-L1 的动态变化,并分析sPD-L1 表达与TNM 分期、远处转移以及胃泌素释放肽前体(pro-gastrin-releasing peptide,ProGRP)的相关性。结果:SCLC组血浆sPD-L1水平高于健康人组(P<0.05和P<0.01)。疾病缓解期的SCLC患者化疗后血浆sPD-L1水平比化疗前显著降低(P<0.01);疾病进展期患者化疗后血浆sPD-L1水平比化疗前显著升高(P<0.01)。SCLC患者sPD-L1异常高表达与疾病进展显著相关(P<0.05)。血浆sPD-L1表达与肿瘤标志物ProGRP呈正相关。结论:SCLC患者外周血浆sPD-L1的表达较健康人增高,且与疗效密切相关。
|
| 关 键 词： | 小细胞肺癌 可溶性程序性死亡配体1 PD-L1表达 |
| 收稿时间： | 2019-03-07 |
Change of peripheral blood sPD- L1 during chemotherapy in patients with small cell lung cancer and its clinical significance |
| |
| Hao Tian,Xiaoyan Kang,Lin Yang,Haibo Zhu,Wei Guo,Xia Song. Change of peripheral blood sPD- L1 during chemotherapy in patients with small cell lung cancer and its clinical significance[J]. Chinese Journal of Clinical Oncology, 2019, 46(9): 452-456. DOI: 10.3969/j.issn.1000-8179.2019.09.272 |
| |
| Authors: | Hao Tian Xiaoyan Kang Lin Yang Haibo Zhu Wei Guo Xia Song |
| |
| Affiliation: | ①.Shanxi Medical University, Taiyuan 030001, China②.Department of Radiotherapy, Shanxi Provincial Cancer Hospital, Taiyuan 030013, China③.No.2 Department of Respiratory Medicine, Shanxi Provincial Cancer Hospital, Taiyuan 030013, China |
| |
| Abstract: | Objective In tumor microenvironment, immune-related mechanisms up-regulate the expression of programmed death ligand 1 (PD-L1), which abnormally activates PD-L1 signaling pathway and mediates tumor immune escape. Soluble programmed death ligand 1 (sPD-L1) is a form of PD-L1. It has been confirmed that the expression of sPD-L1 in lung squamous cell carcinoma and adenocarcinoma is related to disease progression, while small cell lung cancer (SCLC) has a high degree of malignancy, strong invasiveness and few related studies. The purpose of this study was to observe the changes in expression of sPD-L1 in the plasma of SCLC patients and their clinical significance. Methods A total of 94 patients with SCLC diagnosed by pathological examination in Shanxi Provincial Cancer Hospital from March 2018 to November 2018 were selected as test group, and 17 healthy persons in the same period were selected as control group. The dynamic changes of plasma sPD-L1 were compared between the two groups, and the correlations among the expression of sPD-L1 and TNM stage, distant metastasis, and pro-gastrin-releasing peptide (ProGRP) was analyzed. Results The level of sPD-L1 in the test group was higher than that in the control group (P < 0.05 and P < 0.01, respectively). In patients with SCLC in the remission stage, the serum sPD-L1 level after chemotherapy was significantly lower than that before chemotherapy (P < 0.01); in patients with advanced stage, the serum sPD-L1 level after chemotherapy was significantly higher than that before chemotherapy (P < 0.01). The abnormal high expression of sPD-L1 in SCLC patients was significantly correlated with the progression of the disease (P < 0.05). The expression of sPD-L1 in serum was positively correlated with the tumor marker ProGRP. Conclusions The expression of sPDL1 in peripheral plasma of patients with SCLC is higher than that in healthy individuals and is closely related to the clinical effect. |
| |
| Keywords: | small cell lung cancer (SCLC) soluble programmed death ligand 1 (sPD-L1) programmed death ligand 1 (PD-L1) expression |
| 本文献已被 维普 等数据库收录！ |
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
|
点击此处可从《中国肿瘤临床》下载免费的PDF全文 |
|
